.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA15_Alefacept.Alefacept

Information

Alefacept is a recombinant dimeric fusion protein composed of the extracellular CD2-binding portion of human LFA-3 linked to the Fc portion of human IgG1. It was used as an immunosuppressive agent for the treatment of moderate to severe chronic plaque psoriasis. Alefacept is no longer marketed or approved for use in most countries due to concerns over efficacy and safety.

Pharmacokinetics

Pharmacokinetic parameters estimated based on available public summaries for adults with moderate to severe chronic plaque psoriasis; no detailed peer-reviewed pharmacokinetic publication identified for alefacept.

References

1. Ortonne, JP (2003). Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 17 Suppl 2 12–16. DOI:10.1046/j.1468-3083.17.s2.3.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12795770

2. Krueger, GG (2004). Current concepts and review of alefacept in the treatment of psoriasis. Dermatologic clinics 22(4) 407–viii. DOI:10.1016/j.det.2004.03.014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15450337

Revisions

• 06/2025 initial generated model